KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Travere Therapeutics (TVTX) Non-Current Deffered Revenue (2021 - 2024)

Travere Therapeutics' Non-Current Deffered Revenue history spans 4 years, with the latest figure at $888000.0 for Q1 2024.

  • For Q1 2024, Non-Current Deffered Revenue fell 89.88% year-over-year to $888000.0; the TTM value through Mar 2024 reached $888000.0, down 89.88%, while the annual FY2023 figure was $1.8 million, 83.21% down from the prior year.
  • Non-Current Deffered Revenue reached $888000.0 in Q1 2024 per TVTX's latest filing, down from $1.8 million in the prior quarter.
  • In the past five years, Non-Current Deffered Revenue ranged from a high of $24.1 million in Q3 2021 to a low of $888000.0 in Q1 2024.
  • Average Non-Current Deffered Revenue over 4 years is $11.6 million, with a median of $10.9 million recorded in 2022.
  • Peak YoY movement for Non-Current Deffered Revenue: plummeted 46.36% in 2022, then plummeted 89.88% in 2024.
  • A 4-year view of Non-Current Deffered Revenue shows it stood at $20.4 million in 2021, then plummeted by 46.36% to $10.9 million in 2022, then tumbled by 83.21% to $1.8 million in 2023, then crashed by 51.61% to $888000.0 in 2024.
  • Per Business Quant, the three most recent readings for TVTX's Non-Current Deffered Revenue are $888000.0 (Q1 2024), $1.8 million (Q4 2023), and $4.6 million (Q3 2023).